Axa
SIOX

Axa’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Axa’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-51,100
Closed -$262K – 1269
2019
Q4 		$262K Hold
51,100
– – ﹤0.01% 1099
2019
Q3 		$330K Buy
+51,100
New +$352K ﹤0.01% 1167

Other funds holding SIOX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Axa's SIOX Position: Q1 2020 in Review

Axa sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2020, closing a stake of 51,100 shares — an estimated $262K sold.

Axa first reported a position in SIOX in Q3 2019 and held it in 2 quarters. The position peaked at $330K in Q3 2019. 42 funds tracked by Wall St. Rank hold SIOX as of Q1 2020.

  • Axa reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Axa sold 51,100 Sio Gene Therapies Inc. Common Stock shares in Q1 2020, an estimated $262K.
  • Axa first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Axa's Sio Gene Therapies Inc. Common Stock position peaked at $330K in Q3 2019.
  • 42 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2020.

Based on Axa's 13F filing for Q1 2020, filed 15 May 2020.